jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2017-9-4-144-152jofin-668Research ArticleКлинический случайClinical CaseТОКСИЧЕСКИЙ ЭПИДЕРМАЛЬНЫЙ НЕКРОЛИЗ (СИНДРОМ ЛАЙЕЛЛА)TOXIC EPIDERMAL NECROLYSIS (LYELL’S SYNDROME)КуделкаЕ. Н.KudelkaE. N.

Куделка Елена Николаевна – заведующая ОРИТ, врач-анестезиолог-реаниматолог клиники инфекционных болезней (с курсом медицинской паразитологии и тропических заболеваний), кандидат медицинских наук.

 

Saint-Petersburg.

enkudelka07@gmail.ruШахмановД. М.ShakhmanovD. M.

Шахманов Дмитрий Михайлович – старший преподаватель кафедры инфекционных болезней (с курсом медицинской паразитологии и тропических заболеваний),   кандидат медицинских наук.

Saint-Petersburg.

dmitry.shakhmaanov@gmail.ruСоболевА. Ф.SobolevA. F.

Соболев Андрей Фёдорович – начальник учебной части кафедры офтальмологии, кандидат медицинских наук.

Санкт-Петербург.

Saint-Petersburg.

af_sobolev@mail.ruРаводинР. А.RavodinR. A.

Раводин Роман Анатольевич – доцент кафедры дерматовенерологии, кандидат медицинских наук.

 

Saint-Petersburg.

rracad@mail.ruЧаплыгинА. В.ChaplyginA. V.

Чаплыгин Алексей Владимирович –  доцент кафедры дерматовенерологии,   кандидат медицинских наук.

Санкт-Петербург.

Saint-Petersburg.

av-chapl@yandex.ruГусаровМ. В.GusarovM. V.

Гусаров Михаил Вячеславович – заместитель главного врача.

Санкт-Петербург.

Saint-Petersburg.

mvgusarov@gmail.comЯкушенкоС. С.YakushenkoS. S.

Якушенко Сергей Сергеевич – врач-дерматовенеролог. 

Липецк.

Lipetsk.

doctorserg@yandex.ruВоенно-медицинская академия им. С.М. Кирова.РоссияMilitary Medical Academy named after S.M. Kirov.Russian FederationСеверо-Западный государственный медицинский университет им. И.И. Мечникова.РоссияNorth-Western State Medical University named after I.I. Mechnikov.Russian FederationКожно-венерологический диспансер №1.РоссияDermatovenerologic dispensary №1.Russian FederationОбластной кожно-венерологический диспансер.РоссияRegional Dermatovenerologic Dispensary.Russian Federation20171101201894144152Copyright © Куделка Е.Н., Шахманов Д.М., Соболев А.Ф., Раводин Р.А., Чаплыгин А.В., Гусаров М.В., Якушенко С.С., 20182018Куделка Е.Н., Шахманов Д.М., Соболев А.Ф., Раводин Р.А., Чаплыгин А.В., Гусаров М.В., Якушенко С.С.Kudelka E.N., Shakhmanov D.M., Sobolev A.F., Ravodin R.A., Chaplygin A.V., Gusarov M.V., Yakushenko S.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/668

.

.

ReferencesLyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. / Br J Dermatol 1956; 68(11): 355–61.Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. / Br J Dermatol 1956; 68(11): 355–61.Valeyrie-Allanore L., Roujeau Jean-Claude. Epidermal necrolysis (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis). In: Wolf K. et al. Fitzpatrick’s dermatology in general medicine 7th edition, New York: МсGraw-Hill, 2008; 349-355.Valeyrie-Allanore L., Roujeau Jean-Claude. Epidermal necrolysis (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis). In: Wolf K. et al. Fitzpatrick’s dermatology in general medicine 7th edition, New York: МсGraw-Hill, 2008; 349-355.Roujeau J.C., Guillaume J.C., Fabre J.D. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-85. / Arch Dermatol 1990; 126(1): 37-42.Roujeau J.C., Guillaume J.C., Fabre J.D. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-85. / Arch Dermatol 1990; 126(1): 37-42.Saiag P. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immudeficiency virus. / J Am Acad Dermatol 1992; 26(4): 567-74.Saiag P. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immudeficiency virus. / J Am Acad Dermatol 1992; 26(4): 567-74.French LE., Prins C. Erythema multiforme, StevensJohnson syndrome and toxic epidermal necrolysis. / In: Bolognia JL, Jorrizo JL, Schaffer JV editors. Dermatology 3rd edition, New York: Elsevier; 2013; 319–33.French LE., Prins C. Erythema multiforme, StevensJohnson syndrome and toxic epidermal necrolysis. / In: Bolognia JL, Jorrizo JL, Schaffer JV editors. Dermatology 3rd edition, New York: Elsevier; 2013; 319–33.Bastuji-Garin S., Rzany B., Stern R.S. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. / Arch Dermatol 1993; 129(1): 92–6.Bastuji-Garin S., Rzany B., Stern R.S. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. / Arch Dermatol 1993; 129(1): 92–6.Chen P., Lin J.J., Lu C.S. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. / N Engl J Med 2011; 364(12): 1126–33.Chen P., Lin J.J., Lu C.S. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. / N Engl J Med 2011; 364(12): 1126–33.Hung S.I., Chung W.H., Liou L.B. HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. / Proc Natl Acad Sci USA 2005; 102(11): 4134–9.Hung S.I., Chung W.H., Liou L.B. HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. / Proc Natl Acad Sci USA 2005; 102(11): 4134–9.Revuz J., Penso D., Roujeau J.C. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. / Arch Dermatol 1987; 123(9): 1160–5.Revuz J., Penso D., Roujeau J.C. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. / Arch Dermatol 1987; 123(9): 1160–5.Ang C.C., Tay Y.K. / Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. / Int J Dermatol 2011; 50(12): 1570–8.Ang C.C., Tay Y.K. / Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. / Int J Dermatol 2011; 50(12): 1570–8.Lebargy F., Wolkenstein P., Gisselbrecht M. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. / Intensive Care Med 1997; 23(12): 1237–44.Lebargy F., Wolkenstein P., Gisselbrecht M. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. / Intensive Care Med 1997; 23(12): 1237–44.Chang Y.S., Huang F.C., Tseng S.H. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. / Cornea 2007; 26(2): 123–9.Chang Y.S., Huang F.C., Tseng S.H. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. / Cornea 2007; 26(2): 123–9.Yip L.W., Thong B.Y., Lim J. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. / Allergy 2007; 62(5): 527–31.Yip L.W., Thong B.Y., Lim J. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. / Allergy 2007; 62(5): 527–31.Magina S., Lisboa C., Leal V. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. / Dermatology 2003; 207(1): 33–6.Magina S., Lisboa C., Leal V. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. / Dermatology 2003; 207(1): 33–6.Chosidow O., Delchier J.C., Chaumette M.T. / Intestinal involvement in drug-induced toxic epidermal necrolysis. Lancet 1991, 337: 928.Chosidow O., Delchier J.C., Chaumette M.T. / Intestinal involvement in drug-induced toxic epidermal necrolysis. Lancet 1991, 337: 928.Paquet P., Pierard G.E. Erytema multiforme and toxic epidermal necrolysis: a comparative study. / Am J Dermatophatol 1997; 19(2): 127-32.Paquet P., Pierard G.E. Erytema multiforme and toxic epidermal necrolysis: a comparative study. / Am J Dermatophatol 1997; 19(2): 127-32.Schwartz R.A., McDonough P.H., Lee B.W. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. / J Am Acad Dermatol 2013; 69(2): 187.e1–16; quiz 203–4.Schwartz R.A., McDonough P.H., Lee B.W. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. / J Am Acad Dermatol 2013; 69(2): 187.e1–16; quiz 203–4.Rzany B., Schmitt H., Schαpf E. Toxic epidermal necrolysis in patient receiving glucocorticosteroids. / Acta Derm Venerol (Stockh) 1991; 71: 171-2.Rzany B., Schmitt H., Schαpf E. Toxic epidermal necrolysis in patient receiving glucocorticosteroids. / Acta Derm Venerol (Stockh) 1991; 71: 171-2.Van der Meer J.B., Schuttelaar M.L., Toth G.G. Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam. / Clin Exp Dermatol 2001; 26: 654-6.Van der Meer J.B., Schuttelaar M.L., Toth G.G. Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam. / Clin Exp Dermatol 2001; 26: 654-6.Han F., Zhang J. Successful treatment of toxic epidermal necrolysis using plasmapheresis: A prospective observational study. / J Crit Care 2017; 1(42): 65-68.Han F., Zhang J. Successful treatment of toxic epidermal necrolysis using plasmapheresis: A prospective observational study. / J Crit Care 2017; 1(42): 65-68.Barron S.J., Del Vecchio M.T., Aronoff S.C. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with metaregression of observational studies. / Int J Dermatol 2015; 54(1): 108–15.Barron S.J., Del Vecchio M.T., Aronoff S.C. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with metaregression of observational studies. / Int J Dermatol 2015; 54(1): 108–15.Huang Y.C., Li Y.C., Chen T.J. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. / Br J Dermatol 2012; 167(2): 424–32.Huang Y.C., Li Y.C., Chen T.J. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. / Br J Dermatol 2012; 167(2): 424–32.Roujeau J.C., Mockenhaupt M., Guillaume J.C., Revuz J. New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis. / J Invest Dermatol 2017; 137(10): 2047-2049.Roujeau J.C., Mockenhaupt M., Guillaume J.C., Revuz J. New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis. / J Invest Dermatol 2017; 137(10): 2047-2049.Fischer M., Fiedler E., Marsch W.C. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. / J Br J Dermatol 2002; 146(4): 707-9.Fischer M., Fiedler E., Marsch W.C. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. / J Br J Dermatol 2002; 146(4): 707-9.

The authors declare that there are no conflicts of interest present.